In short
This article discusses the ongoing clinical trials of SP-420, a novel drug being tested for the treatment of transfusion-dependent alpha or beta thalassemia. SP-420 is being evaluated in an open-label, dose-escalation, dose-finding, and proof-of-concept trial to assess its effectiveness in removing excess iron from the body and improving the quality of life for patients with these blood disorders.
At a glance
- Drug Name
- SP-420 ((S)-4,5-Dihydro-2-[2-Hydroxy-4-(3,6-Dioxaheptyloxy)Phenyl]-4-Methyl-4-Thiazolecarboxylic Acid)
- Trial Phase
- Phase II
- Trial Design
- Open-label, dose-escalation, dose-finding, and proof-of-concept
- Target Condition
- Transfusion-dependent alpha or beta thalassemia
- Primary Objective
- Establish dose-response relationship of SP-420 for 24 weeks
- Key Secondary Objectives
- Assess efficacy in clearing liver iron, total body iron removal, effects on serum ferritin
- Dosing
- Oral administration, 3 times per week, starting at 28 mg/kg with potential increases
- Trial Duration
- 48 weeks
- Key Inclusion Criteria
- Age ≥18 years, transfusion-dependent thalassemia, stable iron chelation, liver iron concentration ≥5 and ≤35mg/g dw
- Key Exclusion Criteria
- Certain thalassemia variants, significant kidney or heart issues, recent use of other investigational drugs
Introduction to SP-420
SP-420 is a new investigational drug being studied for the treatment of transfusion-dependent thalassemia, a group of inherited blood disorders that affect the body's ability to produce hemoglobin. The active substance in SP-420 is a chemical compound with a long scientific name: (S)-4,5-dihydro-2-[2-hydroxy-4-(3,6-dioxaheptyloxy)phenyl]-4-methyl-4-thiazolecarboxylic acid. This medication is being developed by Pharmacosmos A/S and is currently in Phase II clinical trials.
How SP-420 Works
SP-420 is designed to act as an iron chelator. Iron chelators are medications that bind to excess iron in the body and help remove it. In transfusion-dependent thalassemia, patients receive regular blood transfusions, which can lead to iron overload. SP-420 aims to help remove this excess iron, potentially reducing complications associated with iron buildup in various organs.
Target Conditions: Alpha and Beta Thalassemia
SP-420 is being studied for two main types of thalassemia: Alpha-thalassemia: A condition where the body doesn't produce enough alpha globin, a component of hemoglobin. Beta-thalassemia: A condition where the body doesn't produce enough beta globin, another component of hemoglobin. Both conditions can lead to severe anemia, requiring regular blood transfusions for survival, hence the term "transfusion-dependent".
Current Clinical Trial
The ongoing clinical trial for SP-420 is an open-label, dose-escalation, dose-finding, and proof-of-concept study. This means: Open-label: Both the researchers and participants know which treatment is being given. Dose-escalation: The study starts with a low dose and gradually increases it to find the optimal dose. Dose-finding: The study aims to determine the most effective and safe dose of SP-420. Proof-of-concept: The study seeks to verify that SP-420 works as intended in treating thalassemia.
Dosage and Administration
SP-420 is administered orally in the form of capsules. The study is testing different dosages: Initially, 28 mg/kg taken orally three times per week Potentially increasing to 56 mg/kg taken orally three times per week Possibly escalating to 84 mg/kg taken orally three times per week The maximum daily dose being tested is 84 mg/kg, with a maximum total dose of 12,096 mg/kg over a 48-week treatment period.
Eligibility Criteria
To participate in the SP-420 clinical trial, patients must meet specific criteria. Some key inclusion criteria are: Age 18 years or older Diagnosed with transfusion-dependent alpha- or beta-thalassemia Currently on stable iron chelation therapy Weight of 35 kg or more Evidence of iron overload in the liver There are also several exclusion criteria, including certain medical conditions, medications, and circumstances that would make participation unsafe or potentially interfere with the study results.
Study Objectives
The main objectives of the SP-420 clinical trial include: Establishing the dose-response relationship of SP-420 over 24 weeks Assessing the efficacy of SP-420 in removing iron from the liver Evaluating the drug's ability to remove iron from the entire body Measuring the effect of SP-420 on serum ferritin levels (a measure of iron in the blood) Assessing the safety and tolerability of different doses of SP-420
Study Endpoints
The trial will measure several outcomes, known as endpoints, to determine the effectiveness and safety of SP-420: Primary endpoint: Total body iron removed by SP-420 from baseline to week 24 Secondary endpoints: Changes in liver iron concentration, total body iron removal at different time points, changes in serum ferritin levels, and the occurrence of adverse events
Safety Considerations
As with any clinical trial, patient safety is a top priority. The study includes several measures to monitor and ensure participant safety: Regular monitoring of liver and kidney function Cardiac assessments, including MRI and ECG Monitoring for potential side effects and adverse events A Data Monitoring Committee to oversee the study and make recommendations on dosing Participants will be closely monitored throughout the trial period to ensure their safety and well-being.